LMNA mutation in a patient with progeroid features and dilated cardiomyopathy

2021 ◽  
Vol 132 ◽  
pp. S108-S109
Author(s):  
Katherine Mascia ◽  
Kirstin Smith ◽  
Maria Descartes
2015 ◽  
Vol 29 (S1) ◽  
Author(s):  
Andrea Gerbino ◽  
Monica Carmosino ◽  
Francesca Del Vecchio ◽  
Silvia Torretta ◽  
Giorgia Schena ◽  
...  

2013 ◽  
Vol 319 (19) ◽  
pp. 3010-3019 ◽  
Author(s):  
Rasha Al-Saaidi ◽  
Torsten B. Rasmussen ◽  
Johan Palmfeldt ◽  
Peter H. Nissen ◽  
Abdelaziz Beqqali ◽  
...  

2004 ◽  
Vol 14 (1) ◽  
pp. 155-169 ◽  
Author(s):  
Takuro Arimura ◽  
Anne Helbling-Leclerc ◽  
Catherine Massart ◽  
Shaida Varnous ◽  
Florence Niel ◽  
...  

2008 ◽  
Vol 10 (S1) ◽  
Author(s):  
Kristel M Antila ◽  
Juha R Koikkalainen ◽  
Jyrki MP Lötjönen ◽  
Tiina Heliö ◽  
Sari M Kivistö ◽  
...  

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Xiaolin Zhang ◽  
Xiuli Shao ◽  
Ruijia Zhang ◽  
Rongli Zhu ◽  
Rui Feng

Abstract Background Dilated cardiomyopathy (DCM) is a serious cardiac heterogeneous pathological disease, which may be caused by mutations in the LMNA gene. Lamins interact with not only lamina-associated domains (LADs) but also euchromatin by alone or associates with the lamina-associated polypeptide 2 alpha (LAP2α). Numerous studies have documented that LMNA regulates gene expression by interacting with LADs in heterochromatin. However, the role of LMNA in regulating euchromatin in DCM is poorly understood. Here, we determine the differential binding genes on euchromatin in DCM induced by LMNA mutation by performing an integrated analysis of bioinformatics and explore the possible molecular pathogenesis mechanism. Results Six hundred twenty-three and 4484 differential binding genes were identified by ChIP-seq technology. The ChIP-seq analysis results and matched RNA-Seq transcriptome data were integrated to further validate the differential binding genes of ChIP-seq. Five and 60 candidate genes involved in a series of downstream analysis were identified. Finally, 4 key genes (CREBBP, PPP2R2B, BMP4, and BMP7) were harvested, and these genes may regulate LMNA mutation-induced DCM through WNT/β-catenin or TGFβ-BMP pathways. Conclusions We identified four key genes that may serve as potential biomarkers and novel therapeutic targets. Our study also illuminates the possible molecular pathogenesis mechanism that the abnormal binding between LMNA or LAP2α-lamin A/C complexes and euchromatin DNA in LMNA mutations, which may cause DCM through the changes of CREBBP, PPP2R2B, BMP4, BMP7 expressions, and the dysregulation of WNT/β-catenin or TGFβ-BMP pathways, providing valuable insights to improve the occurrence and development of DCM. Graphic abstract


Author(s):  
Drissa Mariem ◽  
◽  
Yaakoubi Wael ◽  
Helali Sana ◽  
Hbiba Drissa ◽  
...  

Mutation in LMNA accounts for 10% of Dilated Cardiomyopathy (DCM). It is characterised by progressive conduction system disease, arrhythmia and systolic impairment, lamin A/C heart disease is the most malignant gene common in DCMs especially in man. It is likely to be an under-recognised cause of this cardiomyopathy. In certain clinical scenarios, particularly familial DCM with early conduction disease, the probability of finding an LMNA mutation may be quite high.


2020 ◽  
Vol 30 (10) ◽  
pp. 1544-1546
Author(s):  
Kun Li ◽  
Lanting Zhao ◽  
Ping Zhang

AbstractLMNA mutations cause a variety of inherited diseases referred to as laminopathies which are associated with a wide spectrum of disease phenotypes, ranging from skeletal muscle disease, pre-mature ageing, metabolic disorders, and cardiac abnormalities. We present a case of a 14-year-old boy with dilated cardiomyopathy induced by the LMNA mutation (p. R429C) and described its electrocardiogram and imaging features.


Sign in / Sign up

Export Citation Format

Share Document